Reduced cyclooxygenase involvement in vascular endothelial function in rat renal transplantation

Nephron - Physiology

Volumn 100, Issue 2, 2005, Pages

  Smit Van Oosten, Annemieke ^a   Boonstra, Arnold H ^a   Navis, Gerjan ^a   Van Goor, Harry ^a   Buikema, Hendrik ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE; AT1 receptor antagonist; Chronic renal transplant failure; COX; Cyclooxygenase; Indomethacin; L NMMA; Nitric oxide; Rat renal transplantation; Vascular function

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; INDOMETACIN; N(G) METHYLARGININE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOLOGY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOLOGY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; KIDNEY TRANSPLANTATION; MALE; MEMBRANE PROTEINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, INBRED F344; RATS, INBRED LEW; VASOCONSTRICTION; VASODILATION;

EID: 20944434164     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084686     Document Type: Article

References (29)

1. Aker S, Ivens K, Grabensee B, Heering P: Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 1998;30:777-788.
2. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG: Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000;11:S1-S86.
3. Smit-van Oosten A, Navis GJ, Stegeman CA, Joles JA, Klok PA, Kuipers F, Tiebosch ATMG, Van Goor H: Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol 2001;194:122-129.
4. Akcay A, Sezer S, Ozdemir FN, Arat Z, Atac FB, Verdi H, Colak T, Haberal M: Association of the genetic polymorphisms of the reninangiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. Transplantation 2004;78:892-898.
5. Buikema H, Monnink SH, Tio RA, Crijns HJ, De Zeeuw D, Van Gilst WH: Comparison of zofenopril and lisinopril to study the role of the sulfhydryl group in improvement of endothelial dysfunction with ACE inhibitors in experimental heart failure. Br J Pharmacol 2000;130:1999-2007.
6. Teisman AC, Pinto YM, Buikema H, Flesch M, Bohm M, Paul M, van Gilst WH: Dissociation of blood pressure reduction from endorgan damage in TGR(mREN2)27 transgenic rats. J Hypertens 1998;16:1759-1765.
7. Kaplan NM: The challenge of managing multiple cardiovascular risk factors. Am J Hypertens 1997;10:167S-169S.
8. Annuk M, Zilmer M, Fellstrom B: Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int Suppl 2003;84:50-53.
9. Walford G, Loscalzo J: Nitric oxide in vascular biology. J Thromb Haemost 2003;1:2112-2118.
10. Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ: In vivo pharmacology of L158,809, a new highly potent and selective non-peptide angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992;262:139-144.
11. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, Van Gilst WH: The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17:787-794.
12. Raij L, Azar S, Keane WF: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984;26:137-143.
13. Davidge ST: Prostaglandin H synthase and vascular function. Circ Res 2001;89:650-660.
14. Hata AN, Breyer RM: Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147-166.
15. Osiecki H, Dip G: The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev 2004;9:32-53.
16. Victor VM, Rocha M, De la Fuente M: Immune cells: Free radicals and antioxidants in sepsis. Int J Immunopharmacol 2004;4:327-347.
17. Grone HJ, Walli AK, Grone EF: Arterial hypertension and hyperlipedemia as determinants of glomerulosclerosis. Clin Investig 1993;71:834-839.
18. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB: Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994;14: 1021-1031.
19. Yang X, Ma N, Szabolcs MJ, Zhong J, Athan E, Sciacca RR, Michler RE, Anderson GD, Wiese JF, Leahy KM, Gregory S, Cannon PJ: Upregulation of COX-2 during cardiac allograft rejection. Circulation 2000;101:430-438.
20. Baker CS, Hal RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoubl MH, Polak JM: Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999;19:646-655.
21. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998;9:1948-1955.
22. Vaskonen T, Mervaala E, Nevala R, Soots A, Krogerus L, Lahteenmaki T, Karppanen H, Vapaatalo H, Ahonen J: Development of chronic allograft rejection and arterial hypertension in Brown Norway rats after renal transplantation. Blood Press 2000;9:162-168.
23. Mackenzie HS, Ziai F, Nagano H, Azuma H, Troy JL, Rennke HG, Tilney NL, Brenner BM: Candesartan cilexetil reduces chronic renal allograft injury in Fisher-Lewis rats. J Hypertens Suppl 1997;15:21-25.
24. Harris RC, Cheng H, Wang J, Zhang M, McKanna JA: Interactions of the renin-angiotensin system and neuronal nitric oxide synthase in regulation of cyclooxygenase-2 in the macula densa. Acta Physiol Scand 2000;168:47-51.
25. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, Harris RC: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999;103:953-961.
26. Schror K: Converting enzyme inhibitors and the interaction between kinins and eicosanoids. J Cardiovasc Pharmacol 1990;15:S60-S68.
27. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A: Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000;2:64-70.
28. Bakris GL: Angiotensin-converting enzyme inhibition to enhance vascular health - Clinical and research models. Am J Hypertens 2001;14:264S-269S.
29. Curtis JJ: Cyclosporine and posttransplant hypertension. J Am Soc Nephrol 1992;2:S243-S245.